CBF-AML comprises cases with t(8;21)(q22;q22)/RUNX1::RUNX1T1 and inv(16)(p13q22)/t(16;16)/CBFB::MYH11; in pediatrics this subgroup accounts for roughly one-fifth of AML, depending on the cohort. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.